Clinical Trial VICCTHO0547
Title
Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)
Principal Investigator(s)
Details
- Protocol No. VICCTHO0547
- Open Date: 12/19/2005
- Staging: NA
- Age Group: Adults
- Scope: Local
- Objective: From biopsies of lung cancer, we will determine protein and/or RNA expression patterns capable of predicting tumor response to therapy. We will then characterize which genes and proteins are found to be predictive to help elucidate the molecular biology underlying cancer chemosensitivity.
- Disease Sites: Lung; Non Small Cell
- Therapies: Correlative
- Drugs: None Specified
- Participating Institutions: Vanderbilt University
- National Clinical Trial ID: NCT00897650
- Secondary Protocol No: Not Specified
Description
None Provided.
Eligibility
| Ages Eligible for Study: | N/A and older |
|---|---|
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria
• Diagnosis of suspected lung cancer or lung cancer
Exclusion criteria
• Inability to undergo therapy
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
